Himed

Himed is a biomaterials provider specializing in surface treatments for dental and orthopedic implants. Established in 1991, the company has been at the forefront of biomaterial coating characterization and has earned a reputation for quality, consistency, and collaboration in the medical, dental, laboratory, and research industries. Operating from a comprehensive research and production facility in New York, Himed offers raw biomaterials for various purposes and provides highly customizable biocompatible coating and texturing solutions through its MATRIX® line of surface treatments. The company's MATRIX® line includes several innovative solutions such as MATRIX MCD®, which utilizes biocompatible MCD apatitic abrasive for residue-free surface texturing, and MATRIX HA®, applying a dense hydroxyapatite coating on dental implants and medical devices. With ISO 13485:2016 Certification and FDA Medical Device Registration, Himed ensures the highest quality and compliance standards. Although no specific details on the latest investment are available, Himed's focus on cutting-edge biomaterial technologies and its established presence in the health care and manufacturing industries could present an attractive opportunity for potential investors looking to capitalize on advancements in medical technologies. For venture capital firms seeking to support innovative companies in the healthcare sector, Himed presents a promising investment prospect with its proven track record and forward-looking approach to biomaterials.